Brief: Nykode Announces Expanded Clinical Development Plan For Its Lead Cancer Vaccine VB10.16
Dec 20 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE ANNOUNCES EXPANDED CLINICAL DEVELOPMENT PLAN FOR
ITS LEAD
CANCER VACCINE VB10.16 IN HPV16-POSITIVE CANCERS
* NYKODE THERAPEUTICS ASA - DOSE-FINDING PHASE 1/2A TRIAL IN
1ST
LINE PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL
CARCINOMA TO BEGIN IN 1H2023
Source text for Eikon: ID:nGNXbFM9Yy
Further company coverage: NYKD.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026